^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    irinotecan/floxuridine (LY01616)

    i
    Other names: LY01616, LY010616
    Associations

    News

    Trials
    Company:
    Luye Group
    Drug class:
    Topoisomerase I inhibitor, Thymidylate synthase inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=78, Enrolling by invitation, Luye Pharma Group Ltd. | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    irinotecan • irinotecan/floxuridine (LY01616)
    over1year
    Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=78, Enrolling by invitation, Luye Pharma Group Ltd.
    New P1/2 trial • Metastases
    |
    irinotecan • irinotecan/floxuridine (LY01616)